UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event reported): February 15, 2001 COMMISSION FILE NUMBER 1-15943 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as specified in its Charter) DELAWARE 06-1397316 (State of Incorporation) (I.R.S. Employer Identification No.) 251 BALLARDVALE STREET, WILMINGTON, MASSACHUSETTS 01887 (Address of Principal Executive Offices) (Zip Code) 978-658-6000 (Registrant's Telephone Number, Including Area Code) N/A ------------------------------------------------------------ (Former name or former address, if changed since last report) Item 5. Other Events. Attached as Exhibits 99.1, 99.2 and 99.3 are the registrant's consolidated financial statements for the fiscal year ended December 30, 2000 and the registrant's Management's Discussion and Analysis of Financial Condition and Results of Operations. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Charles River Laboratories International, Inc. (Registrant) Dated: February 15, 2001 By: /s/ Thomas F. Ackerman ------------------------------ Thomas F. Ackerman Chief Financial Officer (Principal Financial Officer) and Senior Vice President, Finance and Accounting (Principal Accounting Officer) EXHIBIT INDEX ------------- Exhibit Number Description - -------------- ----------- 23.1 Accountants' Consent 99.1 Consolidated Financial Statements for the fiscal year ended December 30, 2000 99.2 Condensed Financial information schedule 99.3 Management's Discussion and Analysis of Financial Condition and Results of Operations